Difference between revisions of "Medroxyprogesterone acetate (MPA)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
*[[Renal cell carcinoma - historical|Renal cell carcinoma]] | *[[Renal cell carcinoma - historical|Renal cell carcinoma]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1987-08-01: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' medroxyprogesterone acetate, MPA | *'''Generic names:''' medroxyprogesterone acetate, MPA | ||
| Line 23: | Line 25: | ||
[[Category:FDA approved in 1959]] | [[Category:FDA approved in 1959]] | ||
| − | + | [[Category:EMA approved in 1987]] | |
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 12:05, 13 June 2023
Diseases for which it is used
Diseases for which it was used
History of changes in EMA indication
- 1987-08-01: EURD
Also known as
- Generic names: medroxyprogesterone acetate, MPA
- Brand names: Depo-Provera, Provera